Virtual Event | December 5, 2023

mRNA For Cancer Immunotherapy: 2024 Outlook

mRNA-based treatments have already shown great promise as a potent therapeutic agent for cancer immunotherapy. As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS. Cell & Gene Chief Editor Erin Harris hosted expert panelists J. Andrew Case, Head of Supply Chain Cell and Gene Therapies at Genentech/Roche and Daniel Getts, CEO & Co-Founder of Myeloid Therapeutics for a breakdown of ways to address uncoordinated and inefficient processes to promote greater stability and immunogenicity.

access the Virtual Event!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Advancing RNA

Thermo Fisher Scientific Bioproduction